Promising seizure drug for rare genetic disorder enters final testing phase
NCT ID NCT05064878
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 27 times
Summary
This study tests a medicine called ZX008 (fenfluramine) to see if it can safely reduce seizures in children and adults with CDKL5 deficiency disorder, a rare genetic condition that causes severe epilepsy and developmental delays. About 87 participants aged 1 to 35 who have not had success with at least two other seizure treatments will receive either the drug or a placebo. The goal is to measure how much seizure frequency drops and monitor for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CDKL5 DEFICIENCY DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ep0216 101
San Francisco, California, 94158, United States
-
Ep0216 1103
Barcelona, Spain
-
Ep0216 1117
Madrid, Spain
-
Ep0216 1118
Santiago de Compostela, Spain
-
Ep0216 113
Brookline, Massachusetts, 02115, United States
-
Ep0216 120
Philadelphia, Pennsylvania, 19104-4318, United States
-
Ep0216 1201
Florence, Italy
-
Ep0216 1202
Verona, Italy
-
Ep0216 1204
Genova, Italy
-
Ep0216 1206
Roma, Italy
-
Ep0216 1208
Roma, Italy
-
Ep0216 1212
Modena, Italy
-
Ep0216 124
Memphis, Tennessee, 38105, United States
-
Ep0216 134
Detroit, Michigan, 48201, United States
-
Ep0216 1401
Zwolle, Netherlands
-
Ep0216 144
Los Angeles, California, 90095, United States
-
Ep0216 149
Washington D.C., District of Columbia, 20010, United States
-
Ep0216 1502
Shizuoka, Japan
-
Ep0216 1505
Niigata, Japan
-
Ep0216 1512
Hiroshima, Japan
-
Ep0216 1518
Omura-shi, Japan
-
Ep0216 154
Birmingham, Alabama, 35233, United States
-
Ep0216 157
Atlanta, Georgia, 30329, United States
-
Ep0216 164
Cleveland, Ohio, 44195, United States
-
Ep0216 166
Chapel Hill, North Carolina, 27514, United States
-
Ep0216 171
Austin, Texas, 78731, United States
-
Ep0216 173
Aurora, Colorado, 80045, United States
-
Ep0216 1803
Dublin, Ireland
-
Ep0216 1904
Tel Aviv, Israel
-
Ep0216 1906
Ramat Gan, Israel
-
Ep0216 1909
Petah Tikva, Israel
-
Ep0216 2104
Lisbon, Portugal
-
Ep0216 2105
Porto, Portugal
-
Ep0216 2505
Linz, Austria
-
Ep0216 2802
Tbilisi, Georgia
-
Ep0216 3101
Dubai, United Arab Emirates
-
Ep0216 602
London, United Kingdom
-
Ep0216 604
Sheffield, United Kingdom
-
Ep0216 607
Bristol, United Kingdom
-
Ep0216 611
Manchester, United Kingdom
-
Ep0216 801
Edegem, Belgium
-
Ep0216 804
Brussels, Belgium
-
Ep0216 901
Vogtareuth, Germany
-
Ep0216 902
Bielefeld, Germany
-
Ep0216 908
Kiel, Germany
-
Ep0216 909
Kehl-kork, Germany
Conditions
Explore the condition pages connected to this study.